Groups request DRI for omega-3s
This article was originally published in The Tan Sheet
Executive Summary
A consortium of nine scientific, trade and consumer advocacy groups tries to raise support - and funds - for the Institute of Medicine to establish clear dietary reference intakes for EPA and DHA omega-3 fatty acids. IOM needs $1 million to $1.5 million to convene an expert panel to review the fatty acids DRI, says the Global Organization for EPA and DHA Omega-3s in a Nov. 9 release. Along with the Council for Responsible Nutrition, it urges firms to support its IOM petition by visiting 1www.omega3petition.org. GOED notes that a recent issue of PLoS Medicine identified EPA and DHA inadequacy as the sixth leading cause of preventable death in the United States. It adds that establishing DRI for EPA and DHA could save billions in health care costs if consumers know how much of the omega-3s to consume to improve brain and heart health
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.